Transthyretin Amyloidosis Treatment Market Top Players - American Express, Bank of America Corporation, Barclays PLC, Capital One, Citigroup Inc., JPMorgan Chase & Co.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at USD 5.5 Bn in 2024, and it is expected to reach USD 11.7 Bn by the year 2034, with a CAGR of 8.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis (ATTR) is a rare, progressive, and potentially life-threatening disorder caused by the accumulation of misfolded transthyretin proteins in various organs and tissues. Treatment strategies for ATTR primarily focus on pharmacological interventions aimed at stabilizing the transthyretin protein or reducing its production, complemented by supportive care measures to manage symptoms and address disease-related complications.

The global market for ATTR amyloidosis therapies is expected to experience significant growth, driven by rising awareness of the disease and advancements in diagnostic capabilities for rare conditions. The frequent underdiagnosis of ATTR, particularly among patients with chronic health issues, presents a considerable opportunity for early detection and timely intervention. As advanced diagnostic technologies become more widely available, the number of patients eligible for treatment is projected to increase.

Furthermore, increasing investment in clinical research for novel and emerging therapies is supporting market expansion. Public health initiatives led by government agencies, aimed at educating healthcare professionals and the wider population, coupled with improved reimbursement frameworks, are enhancing treatment accessibility and facilitating the adoption of innovative therapeutic solutions on a global scale.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Growth Drivers:
The global market for transthyretin amyloidosis (ATTR) therapies is witnessing significant expansion, primarily driven by the increasing geriatric population, which is projected to grow by approximately 16% to reach 1.5 billion individuals in the coming years. This demographic trend is closely associated with a higher prevalence of ATTR, particularly among older adults. Estimates from Prothena indicate that roughly 400,000 people worldwide are affected by wild-type ATTR (ATTRwt) amyloidosis, while hereditary ATTR (hATTR) amyloidosis affects about 50,000 individuals.

Research from the National Center for Biotechnology Information (NCBI) highlights that ATTRwt predominantly impacts the heart and is strongly correlated with advanced age, emphasizing aging as a key risk factor. Initiatives such as the Australian Amyloidosis Network's biennial traveling workshop have been instrumental in educating healthcare professionals and patients on disease management and therapeutic options.

Challenges:
Despite increased awareness, several barriers continue to impede market growth. Limited knowledge among healthcare providers can result in misdiagnosis, delayed detection, and suboptimal treatment strategies. Additionally, the high cost of recently approved therapies restricts patient access. For example, Alnylam Pharmaceuticals reports an annual treatment cost of approximately USD 450,000 for Patisiran, while Inotersen, another approved therapy, is priced similarly, creating affordability challenges and constraining market penetration.

Regional Insights:
North America is expected to maintain its leading position in the ATTR treatment market, supported by enhanced diagnostic practices, rising prescription rates, and growing adoption of advanced therapies. The approval of ONPATTRO (Patisiran) by Health Canada for the treatment of hATTR polyneuropathy has been a key driver of regional growth.

Meanwhile, the Middle East and Africa are emerging as high-potential markets due to unmet medical needs, increasing disease prevalence, and a growing number of drug approvals. Market expansion in these regions is expected to accelerate, aided by improvements in healthcare infrastructure, heightened awareness, and an expanding patient population.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.